Oxypertine

Summary

Oxypertine (CHEMBL2107011) is an approved small molecule (ATC N05AE01); indicated across 1 condition including psychotic disorder.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: N05AE01
• Indications: 1 condition
• Clinical trials: 1
• Chemistry: 379.5 Da · C23H29N3O2

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL2107011
Name	Oxypertine
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	4640
ATC	N05AE01
Molecular formula	C23H29N3O2
Molecular weight	379.5
InChIKey	XCWPUUGSGHNIDZ-UHFFFAOYSA-N

SMILES: CC1=C(C2=CC(=C(C=C2N1)OC)OC)CCN3CCN(CC3)C4=CC=CC=C4

IUPAC name: 5,6-dimethoxy-2-methyl-3-[2-(4-phenylpiperazin-1-yl)ethyl]-1H-indole

Also known as: Forit, Integrin, Integrin (flavone), Oxipertina, Oxipertine, Oxypertine, WIN-185012, OXYPERTINE, oxypertine

Parent form; salt/anhydrous children: CHEMBL2360489

Patent coverage: 50,055 distinct patent families (173,804 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 173,802 (100%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 18 (assay-derived). Sample: 5-hydroxytryptamine receptor 2B, Alpha-2A adrenergic receptor, Neuronal acetylcholine receptor subunit alpha-4, Alpha-2C adrenergic receptor, Alpha-2B adrenergic receptor, Beta-1 adrenergic receptor, 5-hydroxytryptamine receptor 1A, D(2) dopamine receptor, Sodium-dependent noradrenaline transporter, 5-hydroxytryptamine receptor 2A.

Bioactivity

ChEMBL activities: 14 potent at pChembl ≥ 5 of 19 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
HTR2B	6.92	AC50	120	nM	CHEMBL_ACT_25228186
HTR1A	6.82	AC50	150	nM	CHEMBL_ACT_25216504
ADRA2B	6.6	AC50	250	nM	CHEMBL_ACT_25144384
NR1I2	6.58	AC50	260	nM	CHEMBL_ACT_25188665
HTR2A	6.39	AC50	410	nM	CHEMBL_ACT_25225817
HTR2C	6.31	AC50	490	nM	CHEMBL_ACT_25132480
HRH1	6.19	AC50	645	nM	CHEMBL_ACT_25117065
DRD2	6.04	AC50	920	nM	CHEMBL_ACT_25141032
ADRA2C	5.85	AC50	1400	nM	CHEMBL_ACT_25148584
KCNH2	5.82	AC50	1500	nM	CHEMBL_ACT_25118869
HRH1	5.72	AC50	1900	nM	CHEMBL_ACT_25213218
SLC6A3	5.64	AC50	2300	nM	CHEMBL_ACT_25124641
ADRA2A	5.13	AC50	7400	nM	CHEMBL_ACT_25220558
PDE4D	5.01	AC50	9800	nM	CHEMBL_ACT_25186034

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 indication (1 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
psychotic disorder	4	MONDO:0005485	EFO:0005407

Clinical trials

Total trials: 1.

Phase distribution

Phase	Trials
PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00066196	PHASE2	COMPLETED	Evaluating The Antitumor Activity Of MEDI-522 With Or Without Dacarbazine In Patients With Metastatic Melanoma

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).